Skip to content

Ambispective Registry of Patients Affected by Lung Cancer

Ambispective Registry of Patients Affected by Lung Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07274163
Enrollment
1500
Registered
2025-12-10
Start date
2019-01-01
Completion date
2035-12-31
Last updated
2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

Lung cancer is one of the most common cancers and the leading cause of cancer-related death. It is often diagnosed late, and there are different types of lung cancer. Today, many patients benefit from targeted therapies and immunotherapy, which have improved survival. This study will create an ambispective clinical registry of all lung cancer patients treated at Policlinico San Matteo. The registry will collect data from 2019 to 2035 to better understand: 10-year overall survival, how the disease progresses over time, how patients respond to treatments and possible side effects, how patient and tumor characteristics influence treatment choices, how different therapies work in real-world practice. All data will be securely collected whithin REDCap platform and used to improve future care and research.

Interventions

None listed

Sponsors

Fondazione IRCCS Policlinico San Matteo di Pavia
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients ≥ 18 years diagnosed with and/or treated for lung cancer at the department of SC Oncologia 1 Unit of the Fondazione IRCCS Policlinico San Matteo; * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document; * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease.

Exclusion criteria

* Patients who are unable to understand informed consent document.

Design outcomes

Primary

MeasureTime frame
10 years overall survival10 years

Countries

Italy

Contacts

Primary ContactFrancesco Agustoni
f.agustoni@smatteo.pv.it0382501433

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026